Patterns of end-of-life cancer care differ in Canada and the United States; yet little is known about differences in service-specific and overall costs.
Aim:
The aim of this study was to compare end-of-life costs in Ontario, Canada, and the United States, using administrative health data.
Design:
Advanced-stage nonsmall cell lung cancer patients who died from cancer at age ⩾65.5 years in 2001–2005 were selected from the US Surveillance, Epidemiology, and End Results–Medicare database (N = 16,858) and the Ontario Cancer Registry (N = 8643). We estimated total and service-specific costs (2009 US dollars) in each of the last 6 months of life from the public payer perspectives for short-term and long-term survivors (lived <180 and ⩾180 days post-diagnosis, respectively). Services were defined for comparisons between systems.
Results:
Mean monthly costs increased as death approached, were higher in short-term than long-term survivors, and were generally higher in the United States than in Ontario until the month before death, when they were similar (long-term survivors: US$10,464 and US$10,094 (p = 0.53), short-term survivors US$14,455 and US$12,836 (p = 0.11), in Surveillance, Epidemiology, and End Results–Medicare and Ontario, respectively). Costs for Medicare hospice and Ontario’s palliative care components were similar and increased closer to death. Inpatient hospitalization was the main cost driver with similar costs in both cohorts, despite lower utilization in the United States. The compositions of many services and costs differed.
Conclusion:
Costs for nonsmall cell lung cancer patients were slightly higher in the United States than Ontario until 1 month before death. Administrative data allow exploration and international comparisons of reimbursement policies, health-care delivery, and costs at the end of life.
KrahnMDZagorskiBLaporteA. Healthcare costs associated with prostate cancer: estimates from a population-based study. BJU Int2010; 105: 338–346.
2.
YabroffKRWarrenJLBrownML. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol2007; 4: 643–656.
3.
Institute of Medicine of the Academies. Dying in America: improving quality and honoring individual preferences near the end of life (Key findings and recommendations), 2014, http://www.iom.edu
4.
McCarthyM. US health system is not meeting patients’ needs at end of life, says expert committee. BMJ2014; 349: g5739.
5.
BarberaLPaszatLChartierC. Indicators of poor quality end-of-life cancer care in Ontario. J Palliat Care2006; 22: 12–17.
6.
BrownMLRileyGFSchusslerN. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care2002; 40: IV-104–IV-117.
7.
EarleCCParkERLaiB. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol2003; 21: 1133–1138.
8.
EarleCCNevilleBALandrunMB. Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care2005; 17: 505–509.
9.
WarrenJLBarberaLBremnerKE. End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer I2011; 103: 853–862.
10.
LangtonJMBlanchBDrewAK. Retrospective studies of end-of-life resource utilization and costs in cancer care using health administrative data: a systematic review. Palliat Med2014; 28: 1167–1196.
11.
YabroffKRFrancisciSMariottoA. Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. J Natl Cancer Inst Monogr2013; 46: 1–6.
12.
LipscombJYabroffKRHornbrookMC. Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr2013; 46: 124–130.
13.
WoolhandlerSCampbellTHimmelsteinDU. Costs of health care administration in the United States and Canada. N Engl J Med2003; 349: 768–775.
14.
SpithovenAHGM. Why U.S. health care expenditures and ranking on health care indicators are so different from Canada’s. Int J Health Care Finance Econ2009; 9: 1–24.
15.
RakichJS. The Canadian and U.S. health care systems: profiles and policies. J Healthc Manag1991; 36: 25–42.
16.
WarrenJLKlabundeCNSchragD. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care2002; 40: IV-3–IV-18.
17.
RoscoeLASchonwetterRS. Improving access to hospice and palliative care for patients near the end of life: present status and future direction. J Palliat Care2006; 22: 46–50.
18.
WilsonDMBirchSShepsS. Researching a best-practice end-of-life care model for Canada. Can J Aging2008; 27: 319–330.
HoTHBarberaLSaskinR. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol2011; 29: 1587–1591.
21.
Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian cancer statistics 2012. Toronto, ON, Canada: Canadian Cancer Society, 2012.
22.
American Cancer Society. Cancer facts & figures 2012. Atlanta, GA: American Cancer Society, 2012.
23.
HallSSchulzeKGroomeP. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol2006; 59: 67–76.
24.
ChengSMThompsonLJ. Cancer Care Ontario and integrated cancer programs: portrait of a performance management system and lessons learned. J Health Organ Manag2006; 20: 335–343.
25.
US Public Health Service. International classification of diseases, 9th rev. Washington, DC: US Government Printing Office, 2003.
American Medical Association. Physicians’ current procedural terminology (CPT) 2005. American Medical Association, Chicago, IL, 2004.
28.
US Department of Health and Human Services. Area Resource File (ARF). Rockville, MD: Bureau of Health Professions, Health Resources and Services Administration, 2005.
29.
BurkhardtJHSunshineJH. Core-needle and surgical breast biopsy: comparison of three methods of assessing cost. Radiology1999; 212: 181–188.
30.
BreslowNEDayNE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies (IARC scientific publications no 82). Oxford, UK: Oxford University Press, 1987, pp. 48–79.
31.
Statistics Canada. Your guide to the consumer price index. Catalogue no. 62-557-XPB, 1996, Statistics Canada, Ottawa, ON, Canada.
32.
Statistics Canada. Purchasing power parities and real expenditures, United States and Canada, 2002 to 2009. Ottawa, ON, Canada: Minister of Industry, 2011.
33.
SAS Inc. SAS 9.1 for Unix. Cary, NC: SAS Inc.
34.
SAS Inc. SAS 9.2 for Linux. Cary, NC: SAS Inc.
35.
CrystalSJohnsonRWHarmanJ. Out-of pocket health care costs among older Americans. J Gerontol B Psychol Sci Soc Sci2000; 55: S51–S62.
36.
US Department of Health and Human Services. Welcome to medicare. CMS Publication no. 11095, Centers for Medicare & Medicaid Services, Baltimore, ND, USA, November2014.
37.
CiprianoLERomanusDEarleCC. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health2011; 14: 41–52.
MorishimaTLeeJOtsuboT. Association of healthcare expenditures with aggressive versus palliative care for cancer patients at the end of life: a cross-sectional study using claims data in Japan. Int J Qual Health Care2014; 26: 79–86.
41.
BirdCEShugarmanLRLynnJ. Age and gender differences in health care utilization and spending for medicare beneficiaries in their last years of life. J Palliat Med2002; 5: 705–712.
42.
ShugarmanLRCampbellDEBirdCE. Differences in Medicare expenditures during the last 3 years of life. J Gen Intern Med2004; 19: 127–135.
43.
AuDHUdrisEMFihnSD. Differences in health care utilization at the end of life among patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med2006; 166: 326–331.
44.
DumontSJacobsPTurcotteV. The trajectory of palliative care costs over the last 5 months of life: a Canadian longitudinal study. Palliat Med2010; 24: 630–640.
45.
HillnerBEMcDonaldMKDeschCE. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort. J Clin Oncol1998; 16: 1420–1424.
46.
KaplanRM. Variation between end-of-life health care costs in Los Angeles and San Diego: why are they so different?J Palliat Med2011; 14: 215–220.
47.
PolednakAPShevchenkoIP. Hospital charges for terminal care of cancer patients dying before age 65. J Health Care Finance1998; 25: 26–34.
48.
WalkerHAndersonMFarahatiF. Resource use and costs of end-of-life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care2011; 27: 79–86.
49.
SchnipperLESmithTJRaghavanD. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol2012; 30: 1715–1724.
50.
ShihYCGanzPAAberleD. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol2013; 31: 4151–4157.
51.
DuXLOsborneCGoodwinJS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol2002; 20: 4636–4642.
52.
Baena-CanadaJMEstalella-MendozaSRosado-VarelaP. Use of health-care services during chemotherapy for breast cancer. Eur J Cancer2012; 48: 3328–3334.
53.
TaylorDHJ. The effect of hospice on Medicare and informal care costs: the U.S. experience. J Pain Symptom Manage2009; 38: 110–114.
CutlerDMLyDP. The (paper) work of medicine: understanding international medical costs. J Econ Perspect2011; 25: 3–25.
57.
HuYYKwokACJiangW. High-cost imaging in elderly patients with stage IV cancer. J Natl Cancer Inst2012; 104: 1165–1173.
58.
GroomePAO’SullivanBIrishJC. Management and outcome differences in supraglottic cancer between Ontario, Canada, and the Surveillance, Epidemiology, and End Results areas of the United States. J Clin Oncol2003; 21: 496–505.
59.
FleshnerNRakovitchEKlotzL. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol2000; 163: 1461–1466.
60.
ChungDHerseyKFleshnerN. Differences between urologists in United States and Canada in approach to bladder cancer. Urology2005; 65: 919–925.
61.
BachPBSchragDBeggCB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA2004; 292: 2765–2770.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
